Cellectis S.A. (CLLS)
NASDAQ: CLLS
· Real-Time Price · USD
1.47
0.00 (0.00%)
At close: May 27, 2025, 3:59 PM
1.49
1.36%
After-hours: May 27, 2025, 04:14 PM EDT
Cellectis S.A. Revenue Breakdown
| Period Ending | Dec 31, 2022 |
|---|---|
| Therapeutics Revenue | 25.73M |
| Therapeutics Revenue Growth | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|
| France Revenue | 755K | 19.17M | 30.35M | 51.06M | 7.9M | 12.49M | 24.68M |
| France Revenue Growth | -96.06% | -36.83% | -40.56% | +546.62% | -36.81% | -49.37% | n/a |
| United States Revenue | n/a | n/a | 26.95M | 22.89M | 7.29M | 236K | 508K |
| United States Revenue Growth | n/a | -100.00% | +17.71% | +213.85% | +2990.68% | -53.54% | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 3.45M | 447K | 3.8M | 535K | 161K | 1.56M | 3.95M | 2.82M | 1.7M | 7.64M | 8.42M | 9.28M | 12.49M | 9.68M | 9.34M | 8.78M | 12.49M | 10.3M | 9.07M | 12.15M | 8.77M | 10.97M | 11.82M | 11.49M | 10.52M | 11.56M | 11.25M | 14.01M | 12.99M | 12.15M | 10.42M | 9.77M | 11.98M | 9.77M | 9.56M | 11.93M | 8.85M | 10.8M | 7.7M | 7.79M |
| Selling, General, and Administrative Revenue Growth | +671.59% | -88.24% | +610.75% | +232.30% | -89.66% | -60.58% | +39.97% | +66.20% | -77.78% | -9.21% | -9.31% | -25.70% | +29.10% | +3.55% | +6.44% | -29.72% | +21.24% | +13.58% | -25.33% | +38.45% | -20.01% | -7.20% | +2.88% | +9.22% | -9.04% | +2.79% | -19.73% | +7.85% | +6.91% | +16.67% | +6.60% | -18.45% | +22.58% | +2.20% | -19.85% | +34.86% | -18.10% | +40.30% | -1.16% | n/a |
| Research and Development Revenue | 20.87M | 23.83M | 23.52M | 22.32M | 25.53M | 18.89M | 22.14M | 21.08M | 21.43M | 26.67M | 29.05M | 29.48M | 23.39M | 34.32M | 31.15M | 31M | 23.39M | 20.1M | 22.86M | 20.72M | 30.32M | 21.6M | 25.42M | 14.51M | 21.27M | 18.69M | 18.04M | 18.39M | 20.7M | 20.29M | 19.34M | 19.65M | 19.64M | 15.51M | 21.72M | 21.39M | 17.53M | 15.16M | 14.34M | 6.06M |
| Research and Development Revenue Growth | -12.43% | +1.32% | +5.35% | -12.55% | +35.11% | -14.68% | +5.04% | -1.64% | -19.63% | -8.20% | -1.46% | +26.01% | -31.84% | +10.20% | +0.46% | +32.52% | +16.38% | -12.07% | +10.32% | -31.66% | +40.42% | -15.05% | +75.22% | -31.78% | +13.76% | +3.61% | -1.92% | -11.15% | +2.05% | +4.88% | -1.58% | +0.05% | +26.67% | -28.59% | +1.56% | +21.98% | +15.62% | +5.77% | +136.40% | n/a |